Balyasny Asset Management LLC cut its stake in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 77.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 175,534 shares of the specialty pharmaceutical company’s stock after selling 608,976 shares during the quarter. Balyasny Asset Management LLC owned approximately 0.05% of Valeant Pharmaceuticals International worth $3,037,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Harbor Advisors LLC acquired a new position in Valeant Pharmaceuticals International in the first quarter valued at approximately $110,000. PNC Financial Services Group Inc. lifted its holdings in Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after acquiring an additional 2,763 shares during the period. OLD Mutual Customised Solutions Proprietary Ltd. lifted its holdings in Valeant Pharmaceuticals International by 357.7% in the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,900 shares of the specialty pharmaceutical company’s stock valued at $131,000 after acquiring an additional 9,300 shares during the period. NEXT Financial Group Inc lifted its holdings in Valeant Pharmaceuticals International by 6.2% in the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after acquiring an additional 600 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Valeant Pharmaceuticals International in the first quarter valued at approximately $179,000. 50.48% of the stock is owned by institutional investors.

Shares of Valeant Pharmaceuticals International, Inc. (NYSE VRX) opened at 14.46 on Wednesday. The stock’s 50 day moving average price is $14.02 and its 200 day moving average price is $13.51. The firm’s market cap is $5.04 billion. Valeant Pharmaceuticals International, Inc. has a 12 month low of $8.31 and a 12 month high of $24.30.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The business had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. During the same quarter in the previous year, the firm posted ($0.88) earnings per share. The company’s revenue was down 7.7% compared to the same quarter last year. Equities research analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on VRX shares. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a research note on Sunday, July 30th. BidaskClub downgraded Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research note on Friday, June 16th. Vetr raised Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $13.68 price objective for the company in a research note on Friday, October 6th. Deutsche Bank AG reissued a “hold” rating and issued a $18.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Monday. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Friday, June 30th. Five research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $17.68.

TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/10/11/balyasny-asset-management-llc-has-3-04-million-holdings-in-valeant-pharmaceuticals-international-inc-vrx.html.

In other news, Director Schutter Richard U. De acquired 10,000 shares of the business’s stock in a transaction on Monday, August 21st. The shares were purchased at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.